XSHG
600420
Market cap1.69bUSD
Oct 09, Last price
8.51CNY
1D
1.07%
1Q
-2.07%
Jan 2017
-48.61%
IPO
274.89%
Name
Shanghai Shyndec Pharmaceutical Co Ltd
Chart & performance
P/E
12.09
P/S
1.22
EPS
0.70
Div yield, %
3.56%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
-5.70%
Revenues
9.36b
-14.40%
Net income
944m
-12.85%
CFO
1.70b
-24.73%
Dividend
Sep 18, 20260.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Shyndec Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of pharmaceutical products. The company focuses on five major therapeutic areas: anti-infection, cardiovascular, anti-tumor and immunomodulation, metabolic and endocrine, and anesthesia and psychotropics. It is principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and drug preparations, distributing its products in domestic and overseas markets.
Key people
Chairman of the Board, General Manager · since 2017
Chief Financial Officer · since 2009
Zhong Gong
Deputy General Manager
Dongsong Wei
Secretary of the Board, Deputy General Manager · since 2012
Zhiqun Yang
Deputy General Manager
Min Fu
Chief Quality Officer · since 2007
Zenghe Dong
Director · since 2019
Ming Feng
Director
Zhuozhou Shen
Director
Hao Wang
Director · since 2012
Yisheng Ding
Independent Director · since 2008
Rong Shao
Independent Director · since 2012
Independent Director · since 2012
Independent Director · since 2009
Xudong Zhu
Independent Director · since 2012
Headquarters & legal address
区上海市建陆路378号
浦东新区, SH 100000
CN
浦东新区, SH 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||